The essential target antigens for celiac disease IVD immunoassays are tissue transglutaminase (tTG) and deamidated gliadin peptides (DGP). While endomysium (EMA) antibodies are a classic serological marker, modern ELISA and CLIA kit development focuses on purified recombinant human tTG and synthetic deamidated gliadin peptides as the core raw materials. These two antigens enable high-sensitivity, high-specificity detection of IgA and IgG autoantibodies, and they form the backbone of comprehensive diagnostic panels that address the challenges of selective IgA deficiency and early pediatric screening.
At the heart of celiac serology lie two antigens shaped by the disease process itself: tTG, the enzyme that modifies gluten peptides, and the resulting deamidated gliadin peptides. Using these as capture reagents — in both IgA and IgG formats — lets IVD manufacturers deliver assays that combine >90% sensitivity with specificity approaching 99%, while avoiding the poor performance of native gliadin.
Understanding the Immunological Targets
How Tissue Transglutaminase Becomes a Diagnostic Antigen
tTG is a calcium-dependent enzyme that, in the intestinal submucosa, deamidates glutamine residues in gluten peptides to glutamic acid. This chemical change creates neoantigens that bind strongly to HLA-DQ2 or DQ8 molecules on antigen-presenting cells, driving the T-cell and subsequent B-cell response. The same activated B-cells produce autoantibodies directly against tTG itself, making recombinant human tTG the primary solid-phase antigen for IgA anti-tTG ELISA kits.
The Critical Shift from Native Gliadin to Deamidated Gliadin Peptides
Native gliadin assays suffer from low diagnostic specificity because they detect antibodies to the unmodified protein present in many healthy individuals. In vivo, tTG-mediated deamidation produces negatively charged peptides with vastly enhanced immunoreactivity. By synthesizing deamidated gliadin peptides (DGPs) that mimic these post-translational modifications, kit developers can achieve high specificity and sensitivity in both IgG and IgA formats.
Why Endomysium Is a Diagnostic Marker but Not a Kit Antigen
Endomysial antibodies (EMA) target the same tTG enzyme complexed within the extracellular matrix of smooth muscle tissue. Detection historically relied on indirect immunofluorescence using primate esophagus or umbilical cord sections. Because the molecular identity of the endomysial antigen is tissue transglutaminase, modern immunoassay developers use purified tTG rather than crude tissue substrates, simplifying manufacturing and enabling quantitative automation.
Building a Complete Diagnostic Panel
Dual IgA and IgG Detection Is Non-Negotiable
Approximately 1 in 600 individuals has selective IgA deficiency, with plasma IgA levels below 0.05 g/L. These patients will yield false-negative results on any IgA-based test. Therefore, every comprehensive celiac screening kit must include parallel IgG-based assays. The most reliable antigen for this purpose is deamidated gliadin peptide (DGP) in an IgG format, which demonstrates specificity approaching 99%.
Performance Benchmarks for Antigen Selection
– IgA anti-tTG: sensitivity 91–95%, specificity 95–97% (and often >99% in high-quality recombinant assays).
– IgA anti-DGP: sensitivity 85–90%, specificity ~95%.
– IgG anti-DGP: sensitivity comparable to IgA in pediatric populations, and specificity up to 99%, making it the gold-standard companion for IgA-deficient patients.
– Native gliadin IgA/IgG: poor specificity, often below 80%, and should be avoided as a raw material.
Special Considerations for Pediatric Populations
In children under 3 years of age, IgA anti-tTG responses may not yet be fully developed, while IgG anti-DGP antibodies can offer higher clinical sensitivity. Offering a DGP-based IgG test as part of the panel ensures that early pediatric cases are not missed.
Understanding the Trade-offs
Native Gliadin: Low Cost, High Risk
Some low-cost kits still use intact native gliadin. While manufacturing cost is minimal, the diagnostic specificity penalty is severe, leading to elevated false-positive rates and unnecessary confirmatory biopsies. Regulatory bodies increasingly expect manufacturers to adopt DGP-based reagents.
Recombinant vs. Tissue-Extracted tTG
Tissue-extracted tTG can contain contaminating proteins that cause cross-reactivity. Recombinant human tTG produced in defined expression systems provides superior lot-to-lot consistency and eliminates batch-dependent performance shifts. The modest increase in raw material cost is offset by fewer borderline results and lower customer complaint rates.
The EMA Legacy and Automation Gaps
EMA testing via immunofluorescence remains a confirmatory method in some guidelines, but it is operator-dependent, semi-quantitative, and hard to automate. For IVD manufacturers building scalable, high-throughput platforms, tTG and DGP ELISA/CLIA reagents are the only practical choice.
Making the Right Choice for Your IVD Development Goal
Take a strategic view of your kit’s intended clinical setting and patient population when selecting antigens.
- If your primary focus is building a high-specificity screening panel for large-scale laboratories: Prioritize recombinant human tTG for IgA detection and pair it with a DGP-IgG assay to catch IgA-deficient patients. This combination achieves near-perfect specificity and minimizes false positives.
- If your primary focus is diagnosing celiac disease in children under 3 years: Include DGP-IgG as a mandatory component, as it provides superior sensitivity in this age group compared to tTG-IgA alone.
- If your primary focus is developing a low-cost point-of-care test with acceptable accuracy: Use deamidated gliadin peptides rather than native gliadin, even if it raises per-unit costs slightly — the improvement in specificity directly reduces clinical risk and follow-up burden.
- If your primary focus is monitoring gluten-free diet compliance: tTG-IgA and DGP-IgA assays are suitable, but consider providing a semi-quantitative format that shows declining antibody titers over time, leveraging the same purified antigens.
The antigens you choose define not only your kit’s clinical performance but its market credibility. Anchoring your immunoassay on high-purity tTG and deamidated gliadin peptides ensures you deliver the sensitivity, specificity, and diagnostic completeness that modern guidelines demand.
Summary Table:
| Antigen Target | Primary Format | Sensitivity | Specificity | Development Recommendation |
|---|---|---|---|---|
| Recombinant Human tTG | IgA | 91–95% | 95–97%+ | Essential: Primary solid-phase antigen for high-throughput screening. |
| Deamidated Gliadin Peptides (DGP) | IgG / IgA | 85–90% (IgA) | Up to 99% (IgG) | Essential: Mandatory for pediatric cases & IgA-deficient patient screening. |
| Native Gliadin | IgA / IgG | Variable | < 80% | Avoid: Low specificity leads to high false positives and clinical risk. |
| Tissue Endomysium (EMA) | Indirect IF | High | High | Legacy: Impractical for quantitative, automated IVD kit manufacturing. |
Accelerate Your Celiac Assay Development with CamelBio
Developing high-performance Celiac diagnostic kits requires top-tier raw materials and proven technical expertise. CamelBio provides diagnostic manufacturers, labs, and research institutes with one-stop access to premium IVD raw materials, technical services, and consulting—covering every stage from concept to clinic.
Whether you are optimizing tTG and DGP recombinant antigens or scaling up ELISA/CLIA kit manufacturing, our team is here to support your clinical accuracy and regulatory success.
Contact CamelBio today to request raw material samples or consult with our technical specialists!